Anadys Pharmaceuticals

company

About

Anadys Pharmaceuticals develops novel therapeutics for the treatment of chronic hepatitis C viral infections.

  • 1 - 10

Details

Last Funding Type
Private Equity(PE)
Last Funding Money Raised
$71.30M
Industries
Biotechnology,Health Care
Founded date
Jan 1, 1992
Number Of Employee
1 - 10
Operating Status
Active

Anadys Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections.


The company focuses on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 or TLR7.


Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. As of November 22, 2011, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$71.30M
Anadys Pharmaceuticals has raised a total of $71.30M in funding over 2 rounds. Their latest funding was raised on Aug 11, 2005 from a Private Equity(PE) round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 11, 2005 Private Equity(PE) $71.30M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Anadys Pharmaceuticals is funded by 2 investors. Lotus BioScience Ventures and Coastview Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Lotus BioScience Ventures Private Equity(PE)
Coastview Capital Private Equity(PE)